Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › amrubicin

amrubicin

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of amrubicin

7 trials tracked of amrubicin: 2 in phase 3 or 4.

7Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 5
  1. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  2. Phase 3 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed
  3. Phase 2 Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma Completed
  4. Phase 2 A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer Completed
  5. Phase 2 Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Completed
  6. Phase 2 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer Completed
Show 1 more trials
  1. Phase 2 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC
Pulmonology & Critical Care Phase I
Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC Small study tests new drug combination with radiation for limited-stage small cell lung cancer
A Phase I dose-finding trial in 9 treatment-naïve patients with limited-stage small cell lung cancer established amrubicin 25 mg/m² plus cis…
A new drug combination with radiation showed a 100% response rate and 64.8% five-year survival in early-stage small cell lung cancer patient…
Apr 5, 2026